Regenxbio Q4 2024 GAAP EPS $(1.01) Beats $(1.15) Estimate, Sales $21.21M Miss $23.75M Estimate

Benzinga · 1d ago
Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(1.01) per share which beat the analyst consensus estimate of $(1.15) by 12.17 percent. This is a 29.37 percent increase over losses of $(1.43) per share from the same period last year. The company reported quarterly sales of $21.21 million which missed the analyst consensus estimate of $23.75 million by 10.69 percent. This is a 4.50 percent decrease over sales of $22.21 million the same period last year.